Modeling of Rifampicin-Induced CYP3A4 Activation Dynamics for the Prediction of Clinical Drug-Drug Interactions from In Vitro Data

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Yamashita, Fumiyoshi ^a   Sasa, Yukako ^a   Yoshida, Shuya ^a   Hisaka, Akihiro ^b   Asai, Yoshiyuki ^c   Kitano, Hiroaki ^c,d   Hashida, Mitsuru ^a,e   Suzuki, Hiroshi ^b  

^a KYOTO UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^c OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY GRADUATE UNIVERSITY   (Japan)

^d SONY COMPUTER SCIENCE LABORATORIES INC   (Japan)

^e KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ATORVASTATIN; BUSPIRONE; CYCLOSPORIN; CYTOCHROME P450 3A4; GEFITINIB; IMATINIB; MEFLOQUINE; MIDAZOLAM; NIFEDIPINE; PREDNISOLONE; RIFAMPICIN; SIMVASTATIN; TELITHROMYCIN; TRIAZOLAM; ZOLPIDEM; ZOPICLONE;

AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME SUBSTRATE; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; MOLECULAR DYNAMICS; PREDICTION; PROTEIN EXPRESSION; RNA TRANSLATION;

ANTIBIOTICS, ANTITUBERCULAR; CELLS, CULTURED; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; ENZYME ACTIVATION; HEPATOCYTES; HUMANS; MODELS, THEORETICAL; RIFAMPIN;

EID: 84884540367     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070330     Document Type: Article

References (71)

1. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, et al. (1993) Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 269: 1513-1518.
2. Josephson F, (2010) Drug-drug interactions in the treatment of HIV infection: focus on pharmacokinetic enhancement through CYP3A inhibition. J Intern Med 268: 530-539.
3. Grub S, Bryson H, Goggin T, Lüdin E, Jorga K, (2001) The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients. Eur J Clin Pharmacol 57: 115-121.
4. Capone D, Aiello C, Santoro GA, Gentile A, Stanziale P, et al. (1996) Drug interaction between cyclosporine and two antimicrobial agents, josamycin and rifampicin, in organ-transplanted patients. Int J Clin Pharmacol Res 16: 73-76.
5. Lattes R, Radisic M, Rial M, Argento J, Casadei D, (1999) Tuberculosis in renal transplant recipients. Transpl Infect Dis 1: 98-104.
6. Modry DL, Stinson EB, Oyer PE, Jamieson SW, Baldwin JC, et al. (1985) Acute rejection and massive cyclosporine requirements in heart transplant recipients treated with rifampin. Transplantation 39: 313-314.
7. Kato M, Shitara Y, Sato H, Yoshisue K, Hirano M, et al. (2008) The quantitative prediction of CYP-mediated drug interaction by physiologically based pharmacokinetic modeling. Pharm Res 25: 1891-1901.
8. Galetin A, Burt H, Gibbons L, Houston JB, (2006) Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metab Dispos 34: 166-175.
9. Kanamitsu S, Ito K, Sugiyama Y, (2000) Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver. Pharm Res 17: 336-343.
10. Ito K, Brown HS, Houston JB, (2004) Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 57: 473-486.
11. Kato M, Chiba K, Horikawa M, Sugiyama Y, (2005) The quantitative prediction of in vivo enzyme-induction caused by drug exposure from in vitro information on human hepatocytes. Drug Metab Pharmacokinet 20: 236-243.
12. Shou M, Hayashi M, Pan Y, Xu Y, Morrissey K, et al. (2008) Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction. Drug Metab Dispos 36: 2355-2370.
13. Almond LM, Yang J, Jamei M, Tucker GT, Rostami-Hodjegan A, (2009) Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction. Curr Drug Metab 10: 420-432.
14. Grime K, Ferguson DD, Riley RJ, (2010) The use of HepaRG and human hepatocyte data in predicting CYP induction drug-drug interactions via static equation and dynamic mechanistic modelling approaches. Curr Drug Metab 11: 870-885.
15. Yang J, Liao M, Shou M, Jamei M, Yeo KR, et al. (2008) Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Curr Drug Metab 9: 384-394.
16. Fahmi OA, Hurst S, Plowchalk D, Cook J, Guo F, et al. (2009) Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction. Drug Metab Dispos 37: 1658-1666.
17. Zhang JG, Ho T, Callendrello AL, Crespi CL, Stresser DM, (2010) A multi-endpoint evaluation of cytochrome P450 1A2, 2B6 and 3A4 induction response in human hepatocyte cultures after treatment with β-naphthoflavone, phenobarbital and rifampicin. Drug Metab Lett 4: 185-194.
18. Pascussi JM, Robert A, Nguyen M, Walrant-Debray O, Garabedian M, et al. (2005) Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest 115: 177-186.
19. Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll KM, (2004) The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 199: 193-209.
20. LeCluyse E, Madan A, Hamilton G, Carroll K, DeHaan R, et al. (2000) Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes. J Biochem Mol Toxicol 14: 177-188.
21. Sheiner LB, Grasela TH, (1984) Experience with NONMEM: analysis of routine phenytoin clinical pharmacokinetic data. Drug Metab Rev 15: 293-303.
22. Sheiner LB, Beal SL, (1985) Pharmacokinetic parameter estimates from several least squares procedures: superiority of extended least squares. J Pharmacokinet Biopharm 13: 185-201.
23. Ohno Y, Hisaka A, Suzuki H, (2007) General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. Clin Pharmacokinet 46: 681-696.
24. Ohno Y, Hisaka A, Ueno M, Suzuki H, (2008) General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information. Clin Pharmacokinet 47: 669-680.
25. Backman JT, Luurila H, Neuvonen M, Neuvonen PJ, (2005) Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin Pharmacol Ther 78: 154-167.
26. Bolton AE, Peng B, Hubert M, Krebs-Brown A, Capdeville R, et al. (2004) Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol 53: 102-106.
27. Chung E, Nafziger AN, Kazierad DJ, Bertino JS, (2006) Comparison of midazolam and simvastatin as cytochrome P450 3A probes. Clin Pharmacol Ther 79: 350-361.
28. Kivistö KT, Lamberg TS, Neuvonen PJ, (1999) Interactions of buspirone with itraconazole and rifampicin: effects on the pharmacokinetics of the active 1-(2-pyrimidinyl)-piperazine metabolite of buspirone. Pharmacol Toxicol 84: 94-97.
29. Kyrklund C, Backman JT, Kivistö KT, Neuvonen M, Laitila J, et al. (2000) Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 68: 592-597.
30. McAllister WA, Thompson PJ, Al-Habet SM, Rogers HJ, (1983) Rifampicin reduces effectiveness and bioavailability of prednisolone. Br Med J (Clin Res Ed) 286: 923-925.
31. Swaisland HC, Ranson M, Smith RP, Leadbetter J, Laight A, et al. (2005) Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin Pharmacokinet 44: 1067-1081.
32. Villikka K, Kivistö KT, Lamberg TS, Kantola T, Neuvonen PJ, (1997) Concentrations and effects of zopiclone are greatly reduced by rifampicin. Br J Clin Pharmacol 43: 471-474.
33. Villikka K, Kivistö KT, Luurila H, Neuvonen PJ, (1997) Rifampin reduces plasma concentrations and effects of zolpidem. Clin Pharmacol Ther 62: 629-634.
34. Villikka K, Kivistö KT, Backman JT, Olkkola KT, Neuvonen PJ, (1997) Triazolam is ineffective in patients taking rifampin. Clin Pharmacol Ther 61: 8-14.
35. Schmider J, Brockmöller J, Arold G, Bauer S, Roots I, (1999) Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine. Pharmacogenetics 9: 725-734.
36. Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ, (1992) Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 52: 453-457.
37. Holtbecker N, Fromm MF, Kroemer HK, Ohnhaus EE, Heidemann H, (1996) The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. Drug Metab Dispos 24: 1121-1123.
38. Ridtitid W, Wongnawa M, Mahatthanatrakul W, Chaipol P, Sunbhanich M, (2000) Effect of rifampin on plasma concentrations of mefloquine in healthy volunteers. J Pharm Pharmacol 52: 1265-1269.
39. Shi J, Montay G, Bhargava VO, (2005) Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. Clin Pharmacokinet 44: 915-934.
40. Backman JT, Olkkola KT, Neuvonen PJ, (1996) Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 59: 7-13.
41. Acocella G, Pagani V, Marchetti M, Baroni GC, Nicolis FB, (1971) Kinetic studies on rifampicin. I. Serum concentration analysis in subjects treated with different oral doses over a period of two weeks. Chemotherapy 16: 356-370.
42. Garcia M, Rager J, Wang Q, Strab R, Hidalgo IJ, et al. (2003) Cryopreserved human hepatocytes as alternative in vitro model for cytochrome p450 induction studies. In Vitro Cell Dev Biol Anim 39: 283-287.
43. Hariparsad N, Nallani SC, Sane RS, Buckley DJ, Buckley AR, et al. (2004) Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmacol 44: 1273-1281.
44. Hariparsad N, Carr BA, Evers R, Chu X, (2008) Comparison of immortalized Fa2N-4 cells and human hepatocytes as in vitro models for cytochrome P450 induction. Drug Metab Dispos 36: 1046-1055.
45. Li AP, Jurima-Romet M, (1997) Applications of primary human hepatocytes in the evaluation of pharmacokinetic drug-drug interactions: evaluation of model drugs terfenadine and rifampin. Cell Biol Toxicol 13: 365-374.
46. Prueksaritanont T, Richards KM, Qiu Y, Strong-Basalyga K, Miller A, et al. (2005) Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes. Pharm Res 22: 71-78.
47. Acocella G, (1978) Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet 3: 108-127.
48. Hucka M, Finney A, Sauro HM, Bolouri H, Doyle JC, et al. (2003) The systems biology markup language (SBML): a medium for representation and exchange of biochemical network models. Bioinformatics 19: 524-531.
49. Ghosh S, Matsuoka Y, Asai Y, Hsin KY, Kitano H, (2011) Software for systems biology: from tools to integrated platforms. Nat Rev Genet 12: 821-832.
50. Kitano H, Funahashi A, Matsuoka Y, Oda K, (2005) Using process diagrams for the graphical representation of biological networks. Nat Biotechnol 23: 961-966.
51. Wang YH, (2010) Confidence assessment of the Simcyp time-based approach and a static mathematical model in predicting clinical drug-drug interactions for mechanism-based CYP3A inhibitors. Drug Metab Dispos 38: 1094-1104.
52. Friedman EJ, Fraser IP, Wang YH, Bergman AJ, Li CC, et al. (2011) Effect of different durations and formulations of diltiazem on the single-dose pharmacokinetics of midazolam: how long do we go? J Clin Pharmacol 51: 1561-1570.
53. Ourlin JC, Lasserre F, Pineau T, Fabre JM, Sa-Cunha A, et al. (2003) The small heterodimer partner interacts with the pregnane X receptor and represses its transcriptional activity. Mol Endocrinol 17: 1693-1703.
54. Li T, Chiang JY, (2006) Rifampicin induction of CYP3A4 requires pregnane X receptor cross talk with hepatocyte nuclear factor 4alpha and coactivators, and suppression of small heterodimer partner gene expression. Drug Metab Dispos 34: 756-764.
55. Yang J, Yan B, (2007) Photochemotherapeutic agent 8-methoxypsoralen induces cytochrome P450 3A4 and carboxylesterase HCE2: evidence on an involvement of the pregnane X receptor. Toxicol Sci 95: 13-22.
56. Xie W, Yeuh MF, Radominska-Pandya A, Saini SP, Negishi Y, et al. (2003) Control of steroid, heme, and carcinogen metabolism by nuclear pregnane X receptor and constitutive androstane receptor. Proc Natl Acad Sci U S A 100: 4150-4155.
57. Chen Y, Ferguson SS, Negishi M, Goldstein JA, (2004) Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. J Pharmacol Exp Ther 308: 495-501.
58. Nakajima A, Fukami T, Kobayashi Y, Watanabe A, Nakajima M, et al. (2011) Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine. Biochem Pharmacol 82: 1747-1756.
59. Furesz S, Scotti R, Pallanza R, Mapelli E, (1967) Rifampicin: a new rifamycin. 3. Absorption, distribution, and elimination in man. Arzneimittelforschung 17: 534-537.
60. Poulin P, Theil FP, (2002) Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J Pharm Sci 91: 129-156.
61. Yang J, Liao M, Shou M, Jamei M, Yeo KR, et al. (2008) Cytochrome P450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Curr Drug Metab 9: 384-393.
62. Guidance for industry. drug interaction studies - study design, data analysis, implications for dosing, and labeling recommendations. Available: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf.
63. Chung JY, Cho JY, Lim HS, Kim JR, Yu KS, et al. (2011) Effects of pregnane X receptor (NR1I2) and CYP2B6 genetic polymorphisms on the induction of bupropion hydroxylation by rifampin. Drug Metab Dispos 39: 92-97.
64. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ, Kivistö KT, (2000) Rifampin decreases the plasma concentrations and effects of repaglinide. Clin Pharmacol Ther 68: 495-500.
65. O'Reilly RA, (1974) Interaction of sodium warfarin and rifampicin. studies in man. Ann Intern Med 81: 337-340.
66. Heimark LD, Gibaldi M, Trager WF, O'Reilly RA, Goulart DA, (1987) The mechanism of the warfarin-rifampin drug interaction in humans. Clin Pharmacol Ther 42: 388-394.
67. Chen J, Raymond K, (2006) Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor. Ann Clin Microb Antimicrob 5: 3.
68. Li J, Zhao M, He P, Hidalgo M, Baker SD, (2007) Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res 13: 3731-3737.
69. Nebot N, Crettol S, d'Esposito F, Tattam B, Hibbs DE, et al. (2010) Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes. Br J Pharmacol 161: 1059-1069.
70. Zhang ZY, Chen M, Chen J, Padval MV, Kansra VV, (2009) Biotransformation and in vitro assessment of metabolism-associated drug-drug interaction for CRx-102, a novel combination drug candidate. J Pharm Biomed Anal 50: 200-209.
71. Asai Y, Suzuki Y, Kido Y, Oka H, Heien E, et al. (2008) Specifications of insilicoML 1.0: a multilevel biophysical model description language. J Physiol Sci 58: 447-458.